Sg3 Management, LLC Beam Therapeutics Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $301,500 - $487,900	-10,000 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$39.79 - $70.31 $397,900 - $703,100	10,000 New	10,000 $476,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $397,900 - $703,100	10,000 New	10,000 $476,000
Q4 2021 Feb 15, 2022	BUY	$68.02 - $99.06 $1.36 Million - $1.98 Million	20,000 New	20,000 $1.59 Million
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $2.7 Million - $4.28 Million	-32,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $10.3 Million - $20.6 Million	-160,000 Reduced 83.33%	32,000 $4.12 Million
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $13.7 Million - $23.2 Million	192,000 New	192,000 $15.4 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.